Home Clinical Trials Update

Clinical Trials Update

First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer

A first patient has been dosed in the dose-expansion cohort of the Phase I study with STRO-002, a folate...
Speakers and attendees during Global Capacity Building Showcase at the American Society of Hematology 61th Annual Meeting at the Orange County Convention Center on Sunday December 8, 2019. Photo Courtesy 2019 © ASH/Nick Agro

ASH 2020: Preclinical Models Identify CD74 as Potential Target for the Treatment of Acute...

Presentations during the virtual 62nd American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1 dose-escalation clinical...

ASH 2020: ECHELON-1 and ECHELON-2 and other Results with Brentuximab Vedotin

Presentations discussing brentuximab vedotin (Adcetris®; Seagen/Takeda) presented during the 62nd American Society of Hematology (ASH) Annual, Meeting, and Exposition,...

ASH 2020: Positive Interim Phase I Study Results of TRPH-222 in Patients with R/R...

TRPH-222 (CD22-4AP), an antibody-drug conjugate (ADC) being developed by Triphase, demonstrated early signs of efficacy with favorable tolerability at...

What to Expect at SABCS 2020: New Data for HER2 and HER3 Directed DXd...

New research data for trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki; Enhertu®; Daiichi Sankyo) and patritumab deruxtecan (U3-1402; HER3-DXd), two DXd antibody-drug...

U.S. FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine

The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for loncastuximab tesirine, previously known...

FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment...

The U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) from ADC Therapeutics for loncastuximab...

Huadong Medicine and ImmunoGen Sign Strategic Agreement to Develop and Commercialize Mirvetuximab Soravtansine

ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., a wholly-owned subsidiary of Huadong Medicine Co., Chinese pharmaceutical company founded in...

IMGN632 Receives Breakthrough Therapy Designation in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632, a novel CD123-targeting Antibody-drug Conjugate...

Cetuximab Saratolacan Approved in Japan for the Treatment of Unresectable Locally Advanced and Recurrent...

Japan’s Ministry of Health, Labour and Welfare has approved cetuximab saratolacan sodium (previously known as RM-1929; Akalux® IV Infusion...